Kai-Yue Cao
Overview
Explore the profile of Kai-Yue Cao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
78
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cao K, Zhang D, Bai L, Yan T, Chen Y, Jiang Y, et al.
Noncoding RNA Res
. 2024 Dec;
11:38-47.
PMID: 39736854
Despite the discovery of numerous oncogenes in colorectal cancer (CRC), the development of associated drugs is limited, posing a significant challenge for CRC treatment. Identification of novel druggable targets is...
2.
Zhang D, Yau L, Bai L, Tong T, Cao K, Yan T, et al.
J Pharm Pharmacol
. 2023 Oct;
75(12):1569-1580.
PMID: 37862582
Objectives: This study addresses the bioavailability challenges associated with oral nicotinamide mononucleotide (NMN) administration by introducing an innovative NMN formulation incorporated with hydroxyapatite (NMN-HAP). Methods: The NMN-HAP was developed using...
3.
Ren F, Cao K, Gong R, Yu M, Tao P, Xiao Y, et al.
Int J Biol Macromol
. 2023 Jan;
229:885-895.
PMID: 36603719
Ganoderma lucidum (Ganoderma) is a famous Chinese herbal medicine which has been used clinically for thousands of years in China. Despite numerous studies on triterpenes and polysaccharides, the bioactivity of...
4.
Hu K, Yan T, Cao K, Li F, Ma X, Lai Q, et al.
Mol Ther Nucleic Acids
. 2022 Sep;
29:672-688.
PMID: 36090756
Traditional Chinese medicines (TCMs) have been widely used for treating ischemic heart disease (IHD), and secondary metabolites are generally regarded as their pharmacologically active components. However, the effects of nucleic...
5.
Cao K, Pan Y, Yan T, Tao P, Xiao Y, Jiang Z
mSystems
. 2022 Apr;
7(2):e0016422.
PMID: 35400173
tRNAs purified from non-pathogenic Escherichia coli strains (NPECSs) possess cytotoxic properties on colorectal cancer cells. In the present study, the bioactivity of tRNA halves and tRNA fragments (tRFs) derived from...
6.
Cao K, Yan T, Zhang J, Chan T, Li J, Li C, et al.
Mol Ther Nucleic Acids
. 2022 Mar;
27:718-732.
PMID: 35317282
Drug discovery from plants usually focuses on small molecules rather than such biological macromolecules as RNAs. Although plant transfer RNA (tRNA)-derived fragment (tRF) has been associated with the developmental and...
7.
Shu X, Cao K, Liu H, Yu L, Sun L, Yang Z, et al.
Stem Cell Res Ther
. 2021 Feb;
12(1):119.
PMID: 33579362
Background: Tumor-associated antigens (TAAs) can be targeted in cancer therapy. We previously identified a monoclonal antibody (mAb) 12C7, which presented anti-tumor activity in lung cancer stem cells (LCSCs). Here, we...
8.
Yan T, Pan Y, Yu M, Hu K, Cao K, Jiang Z
Anal Chem
. 2020 Dec;
93(3):1423-1432.
PMID: 33382261
Transfer RNAs (tRNAs) are the most heavily modified RNA species. Liquid chromatography coupled with mass spectrometry (LC-MS/MS) is a powerful tool for characterizing tRNA modifications, which involves pretreating tRNAs with...
9.
Cao K, Pan Y, Yan T, Jiang Z
Int J Biol Macromol
. 2019 Oct;
142:355-365.
PMID: 31593735
Transfer RNAs (tRNAs) are the most abundant class in small non-coding RNAs which have been proved to be pharmacologically active. In the present study, we evaluated the potential anticancer activities...
10.
Hu Z, Yan J, Cao K, Yin Z, Xin W, Zhang M
Dis Markers
. 2019 Sep;
2019:9436047.
PMID: 31481985
Background: MCOLN1 (mucolipin subfamily, member 1) was first identified as an autophagic regulator, which was essential for efficient fusion of both autophagosomes and late endosomes with lysosomes. This study is...